Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Revance Therapeutics stock

RVNC
US7613301099
A1XD3D

Price

0
Today +/-
-0
Today %
-0 %
P

Revance Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Revance Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Revance Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Revance Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Revance Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Revance Therapeutics Stock Price History

DateRevance Therapeutics Price
9/30/20240 undefined
9/27/20240 undefined
9/26/20240 undefined
9/25/20240 undefined
9/24/20240 undefined
9/23/20240 undefined
9/20/20240 undefined
9/19/20240 undefined
9/18/20240 undefined
9/17/20240 undefined
9/16/20240 undefined
9/13/20240 undefined
9/12/20240 undefined
9/11/20240 undefined
9/10/20240 undefined
9/9/20240 undefined
9/6/20240 undefined
9/5/20240 undefined
9/4/20240 undefined
9/3/20240 undefined

Revance Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Revance Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Revance Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Revance Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Revance Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Revance Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Revance Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Revance Therapeutics’s growth potential.

Revance Therapeutics Revenue, EBIT and net profit per share

DateRevance Therapeutics RevenueRevance Therapeutics EBITRevance Therapeutics Net Income
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined

Revance Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0000000301577132234281370470607738817
----------413.3371.4377.2720.0931.6727.0329.1521.5810.70
---------66.6770.1360.6167.95------
000000000105480159000000
-27-43-38-52-72-79-117-142-164-273-274-272-220-156-721551290
--------4,733.33--1,820.00-355.84-206.06-94.02-55.52-19.460.219.0617.48-
-44-580-62-73-89-120-142-159-282-281-356-323-149-691181142173
-31.82--17.7421.9234.8318.3311.9777.36-0.3526.69-9.27-53.87-53.69-115.94636.3675.3121.83
17.717.717.719.424.328.130.136.243.55867.572.784.6000000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Revance Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Revance Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
29.64.13.9171252.3185.5282.9175.8290.1436.5225.1340.7253.92
00.10.20.30.20.102701.83.311.327.68
000005.90000000
0000000005.910.218.345.58
0.51.30.61.41.51.22.25.16.55.87.54.411.7
30.15.54.7172.7254192.7285.1207.9296.6450246.1374.7338.87
8.4714.319.319.710.69.314.441.347.16967.890.21
00001.800000000
0000000000000
00000000071.355.3279.81
00000000014714777.20
1.413.50.50.41.11.242.44.813.735.239.57
9.8817.819.821.911.710.518.443.7270.2285207.2139.59
39.913.522.5192.5275.9204.4295.6226.3340.3720.2531.1581.9478.45
                         
95.495.4124000000.10.10.10.10.09
000.040.440.590.60.810.831.071.51.471.771.93
-160.1-218.3-195.9-258.8-332.3-421.5-542.2-684.8-844.2-1,126.3-1,398-1,754.4-2,078.36
00000000000-40014
0000000000000
-60.1-121.3-33.6176.3253.2177.1268.8145.6225.5374.368.512.6-151.6
0.81.85.53.12.73.86.88.4812.710.64.513.81
2.75.63.63.75.511.811.514.421.935.942.95756.34
0.915.115.60.40.70.70.79.111.112.413.813.413.92
0000000000000
4.695.422.92.93.13.51.900000.75.15
9117.947.610.11219.820.931.9416167.375.689.22
64.911.43.90.65.31.9000180.5280.6379.4426.6
0000000000000
26.25.44.85.35.25.8648.873.8104.4114.8114.2114.24
91.116.88.75.910.57.7648.873.8284.9395.4493.6540.83
100.1134.756.31622.527.526.980.7114.8345.9462.7569.2630.06
4013.422.7192.3275.7204.6295.7226.3340.3720.2531.2581.8478.45
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Revance Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Revance Therapeutics's financial health and stability.

Assets

Revance Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Revance Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Revance Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Revance Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-44-58-52-62-73-89-120-142-159-282-281-356-323
11122111210193311
000000000-2000
0-7-8-10226223439-40-43
1424112225373030349288180187
321100000251215
0000000030000
-28-38-47-55-55-59-95-104-106-178-221-193-216
00-6-6-3-1-2-6-3-4-10-3-6
00-6-6-56-75118-107-1712-29-138109
0000-53-73121-100-1416-19-135116
0000000000000
541313-5-5-3-30027808730
0040236148120052239038252115
541353229142-2195122133129331136
----1.00---1.00-2.00-2.00-37.00-8.00-8.00-9.00
0000000000000
25-25016730-137219-20997165-221029
-28.56-39.23-54.24-62.05-59-61.5-97.87-111.24-109.4-182.72-231.92-196.76-223.46
0000000000000

Revance Therapeutics stock margins

The Revance Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Revance Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Revance Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Revance Therapeutics's sales revenue. A higher gross margin percentage indicates that the Revance Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Revance Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Revance Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Revance Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Revance Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Revance Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Revance Therapeutics Margin History

Revance Therapeutics Gross marginRevance Therapeutics Profit marginRevance Therapeutics EBIT marginRevance Therapeutics Profit margin
2029e0 %0 %0 %
2028e0 %0 %0 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %

Revance Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Revance Therapeutics earnings per share therefore indicates how much revenue Revance Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Revance Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Revance Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Revance Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Revance Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Revance Therapeutics Revenue, EBIT and net profit per share

DateRevance Therapeutics Sales per ShareRevance Therapeutics EBIT per shareRevance Therapeutics Earnings per Share
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined

Revance Therapeutics business model

Revance Therapeutics Inc is a US-based biopharmaceutical company that specializes in the development and marketing of novel treatments in dermatology, neurology, and aesthetic medicine. The company was founded in 2002 and is headquartered in Newark, California. Translated: Revance Therapeutics Inc is a US-based biopharmaceutical company that specializes in the development and marketing of novel treatments in dermatology, neurology, and aesthetic medicine. The company was founded in 2002 and is headquartered in Newark, California. Revance Therapeutics is one of the most popular companies on Eulerpool.com.

Revance Therapeutics SWOT Analysis

Strengths

Revance Therapeutics Inc operates in the highly profitable pharmaceutical industry, which offers significant growth potential and revenue opportunities. The company has a strong portfolio of innovative products and technologies that differentiate it from competitors. Its flagship product, DAXI, has shown promising results in clinical trials, positioning it for potential market success. Revance also has an established network of partnerships with leading healthcare providers and research institutions, enhancing its credibility and access to resources.

Weaknesses

One weakness for Revance Therapeutics is its heavy reliance on a single product, DAXI, which exposes the company to significant risk if it does not meet expectations or faces regulatory hurdles. Moreover, as a relatively small player in the industry, Revance may struggle to compete against larger pharmaceutical companies with greater financial resources and established market presence. The company also faces the challenge of high research and development costs, which can impact profitability.

Opportunities

Revance Therapeutics has several opportunities for growth and expansion. By leveraging its partnerships, the company can tap into new markets and reach a wider customer base. The increasing focus on aesthetics and anti-aging treatments presents a favorable market environment for Revance's innovative products. Additionally, the shifting regulatory landscape and potential policy changes may create opportunities for accelerated product approvals and market entry.

Threats

The pharmaceutical industry is highly competitive and constantly evolving, presenting threats to Revance Therapeutics. The company faces the risk of new entrants introducing alternative products or technologies that could disrupt the market. Regulatory challenges and delays in receiving approvals can also pose threats to Revance's product development and commercialization plans. Furthermore, intellectual property issues and potential legal disputes may hamper the company's ability to protect its innovations and maintain market exclusivity.

Revance Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Revance Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Revance Therapeutics shares outstanding

The number of shares was Revance Therapeutics in 2023 — This indicates how many shares 84.599 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Revance Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Revance Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Revance Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Revance Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Revance Therapeutics.

Revance Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240 0  (33.41 %)2024 Q2
3/31/20240 0  (24.18 %)2024 Q1
12/31/20230 0  (16.06 %)2023 Q4
9/30/20230 0  (-87.33 %)2023 Q3
6/30/20230 0  (-0.84 %)2023 Q2
3/31/20230 0  (-3.83 %)2023 Q1
12/31/20220 0  (1.86 %)2022 Q4
9/30/20220 0  (-28.28 %)2022 Q3
6/30/20220 0  (-0.32 %)2022 Q2
3/31/20220 0  (-10.37 %)2022 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Revance Therapeutics stock

Eulerpool World ESG Rating (EESG©)

34/ 100

🌱 Environment

21

👫 Social

30

🏛️ Governance

52

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees55
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Revance Therapeutics shareholders

%
Name
Stocks
Change
Date
6.44751 % BlackRock Institutional Trust Company, N.A.6,717,017777,76812/31/2023
6.28796 % Teoxane SA6,550,8002,105,00010/20/2023
5.59213 % GIC Private Limited5,825,881332,91612/31/2023
5.02715 % Palo Alto Investors LP5,237,2848,67512/31/2023
4.85144 % The Vanguard Group, Inc.5,054,228278,16612/31/2023
4.51684 % Franklin Advisers, Inc.4,705,640708,64412/31/2023
3.04208 % Polar Capital LLP3,169,239-991,07212/31/2023
2.45611 % JP Morgan Asset Management2,558,779-32,48612/31/2023
2.42052 % State Street Global Advisors (US)2,521,693188,58512/31/2023
11.46005 % Capital World Investors11,939,076-21,74412/31/2023
1
2
3
4
5
...
10

Revance Therapeutics Executives and Management Board

Mr. Mark Foley57
Revance Therapeutics Chief Executive Officer, Director (since 2017)
Compensation 6.61 M
Mr. Dustin Sjuts43
Revance Therapeutics President
Compensation 2.59 M
Mr. Tobin Schilke48
Revance Therapeutics Chief Financial Officer
Compensation 2.28 M
Mr. Dwight Moxie47
Revance Therapeutics Senior Vice President, General Counsel, Corporate Secretary
Compensation 2.27 M
Mr. Angus Russell67
Revance Therapeutics Independent Chairman of the Board
Compensation 328,010
1
2
3

Most common questions regarding Revance Therapeutics

What values and corporate philosophy does Revance Therapeutics represent?

Revance Therapeutics Inc represents values and a corporate philosophy focused on innovative medical solutions. The company is dedicated to developing and commercializing novel therapies for aesthetic and therapeutic indications. With their advanced proprietary technology, Revance aims to provide safe, effective, and long-lasting products to patients worldwide. By leveraging their expertise in neuromodulators and biotechnology, they strive to deliver groundbreaking treatments that meet the diverse needs of physicians and their patients. Revance Therapeutics Inc aims to establish itself as a trusted leader in the pharmaceutical industry through continuous research, development, and commitment to improving patient outcomes.

In which countries and regions is Revance Therapeutics primarily present?

Revance Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Revance Therapeutics achieved?

Revance Therapeutics Inc has accomplished several significant milestones. One notable achievement is the development of DaxibotulinumtoxinA, their proprietary neuromodulator for aesthetic and therapeutic applications. The company also received approval for DaxibotulinumtoxinA by the United States Food and Drug Administration (FDA) for the treatment of glabellar lines in adults. Furthermore, Revance Therapeutics Inc successfully completed multiple clinical trials, demonstrating the safety and efficacy of their innovative products. These achievements highlight Revance Therapeutics Inc's commitment to groundbreaking research, development, and regulatory success in the field of neurotoxins.

What is the history and background of the company Revance Therapeutics?

Revance Therapeutics Inc is a renowned biotechnology company specializing in developing innovative cosmetic and therapeutic products. Established in 2002, Revance has emerged as a leader in advanced neuromodulator technology. With a strong focus on scientific research and clinical development, the company has successfully introduced breakthrough treatments for aesthetic and therapeutic purposes. Revance's proprietary drug delivery platform, known as TransMTS®, allows for precise and long-lasting results. Their notable achievements include FDA approval for DaxibotulinumtoxinA for Injection, a potent and next-generation Botox alternative. Revance Therapeutics Inc continues to revolutionize the industry, providing top-quality products and driving advancements in medical aesthetics.

Who are the main competitors of Revance Therapeutics in the market?

The main competitors of Revance Therapeutics Inc in the market include Allergan plc, Johnson & Johnson, and Medytox Inc.

In which industries is Revance Therapeutics primarily active?

Revance Therapeutics Inc is primarily active in the healthcare and biotechnology industries.

What is the business model of Revance Therapeutics?

Revance Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative aesthetic and therapeutic products. Their business model revolves around utilizing their proprietary peptide technology to develop next-generation neuromodulators and dermal fillers. By leveraging their expertise in drug delivery and using the power of botulinum toxins, Revance aims to provide long-lasting, reliable, and safe treatments for a wide range of medical and aesthetic conditions. Through a combination of rigorous research, clinical trials, and strategic partnerships, Revance Therapeutics Inc aims to revolutionize the field of aesthetics and offer novel solutions to patients worldwide.

What is the P/E ratio of Revance Therapeutics 2024?

The P/E ratio cannot be calculated for Revance Therapeutics at the moment.

What is the P/S ratio of Revance Therapeutics 2024?

The P/S cannot be calculated for Revance Therapeutics currently.

What is the AlleAktien quality score of Revance Therapeutics?

The AlleAktien quality score for Revance Therapeutics is 7/10.

What is the revenue of Revance Therapeutics 2024?

The revenue cannot currently be calculated for Revance Therapeutics.

How high is the profit of Revance Therapeutics 2024?

The profit cannot currently be calculated for Revance Therapeutics.

What is the business model of Revance Therapeutics

Revance Therapeutics Inc. is a biopharmaceutical company that develops innovative technologies in collaboration with its business partners to revolutionize the healthcare market. The company was founded in 2002 and is headquartered in Newark, California. Revance Therapeutics specializes in the development of novel therapies for neurological, dermatological, and aesthetic indications. Revance Therapeutics has three different business segments: drug development, aesthetic medicine, and the sale of licensed technologies. Drug development: Revance Therapeutics has several drugs in the developmental phase for neurological and dermatological applications. One of these drugs is DaxibotulinumtoxinA, a botulinum toxin-like preparation developed for the treatment of uncontrolled saliva flow in patients with neurological disorders such as ALS (Amyotrophic Lateral Sclerosis) and MS (Multiple Sclerosis). Additionally, Revance Therapeutics is in advanced development for a topical product designed to treat chronically inflammatory skin diseases such as psoriasis and eczema. Aesthetic medicine: Revance Therapeutics operates an aesthetic medicine division that offers botulinum toxin preparations for aesthetic purposes such as reducing wrinkles and lifting the face. The company has developed a novel botulinum toxin preparation called DaxibotulinumtoxinA, which is in clinical trials for use in aesthetic medicine. The company also develops injectable fillers for aesthetic applications such as non-surgical nose correction. Licensed technologies: Revance Therapeutics offers its proprietary Aesthetic Delivery Platform technology (RTP technology) for sale to other companies. This technology allows for precise injection of botulinum toxin preparations and fillers into the skin, increasing the effectiveness and safety of injectable treatments and offering patients better results. Overall, Revance Therapeutics aims to develop first-class treatments for healthcare and beauty applications. The company is dedicated to conducting clinical trials to test the effectiveness and safety of its products. Over the years, Revance Therapeutics has received several investments from leading financial and institutional investors who recognize the company's potential to revolutionize the healthcare market. In the future, Revance Therapeutics plans to further expand its product range and develop innovative technologies to create a wider range of applications in healthcare and aesthetic medicine. The company strives to become the leading force in the field of botulinum toxin products and dermatological solutions.

What is the Revance Therapeutics dividend?

Revance Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Revance Therapeutics pay dividends?

The dividend cannot currently be calculated for Revance Therapeutics or the company does not pay out a dividend.

What is the Revance Therapeutics ISIN?

The ISIN of Revance Therapeutics is US7613301099.

What is the Revance Therapeutics WKN?

The WKN of Revance Therapeutics is A1XD3D.

What is the Revance Therapeutics ticker?

The ticker of Revance Therapeutics is RVNC.

How much dividend does Revance Therapeutics pay?

Over the past 12 months, Revance Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Revance Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Revance Therapeutics?

The current dividend yield of Revance Therapeutics is .

When does Revance Therapeutics pay dividends?

Revance Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Revance Therapeutics?

Revance Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Revance Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Revance Therapeutics located?

Revance Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Revance Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Revance Therapeutics from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Revance Therapeutics pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Revance Therapeutics in the year 2023?

In the year 2023, Revance Therapeutics distributed 0 USD as dividends.

In which currency does Revance Therapeutics pay out the dividend?

The dividends of Revance Therapeutics are distributed in USD.

All fundamentals about Revance Therapeutics

Our stock analysis for Revance Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Revance Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.